Public Policy

How Will Bizengri Impact Rare Bile Duct Cancer Treatment?
Public Policy How Will Bizengri Impact Rare Bile Duct Cancer Treatment?

Faisal Zain stands at the forefront of medical technology and pharmaceutical innovation, bringing years of expertise in the manufacturing of complex diagnostic and therapeutic devices. His work has been instrumental in bridging the gap between laboratory breakthroughs and clinical application,

Single-Payer Healthcare Becomes a Litmus Test for California Candidates
Public Policy Single-Payer Healthcare Becomes a Litmus Test for California Candidates

The political landscape of California is currently undergoing a seismic transformation as the race to succeed Governor Gavin Newsom intensifies, placing the ambitious and controversial proposal of a single-payer healthcare system at the very heart of the Democratic primary. What was once considered

Will the RAPID Pathway Finally Close the Medtech Coverage Gap?
Public Policy Will the RAPID Pathway Finally Close the Medtech Coverage Gap?

For decades, the arduous journey of a life-saving medical device often ground to a halt the moment it achieved regulatory approval, leaving patients waiting in a bureaucratic limbo known as the coverage gap. This systemic inefficiency has long been a source of frustration for innovators and

Why Is Trust More Important Than Tech in Health Plans?
Public Policy Why Is Trust More Important Than Tech in Health Plans?

Achieving genuine health equity requires moving beyond flashy digital interfaces and addressing the deep-seated skepticism that vulnerable populations often feel toward administrative institutions. While the healthcare industry frequently champions the idea of meeting members where they are, the

Are Drug Coupons Saving You Money or Raising Your Costs?
Public Policy Are Drug Coupons Saving You Money or Raising Your Costs?

The shimmering plastic card handed over at the pharmacy register often feels like a golden ticket when it magically transforms a staggering five-hundred-dollar bill into a manageable ten-dollar copay. This immediate relief at the checkout counter is the entry point into a multi-billion-dollar

Trump’s Drug Pricing Strategy Yields Selective Cost Relief
Public Policy Trump’s Drug Pricing Strategy Yields Selective Cost Relief

Navigating the labyrinth of American pharmaceutical pricing requires a blend of economic scrutiny and a deep understanding of policy maneuvers that often happen behind closed doors. With over 80% of Americans viewing drug costs as unreasonable and 60% of adults expressing deep-seated worry about

Loading

Subscribe to our weekly news digest

Keep up to date with the latest news and events

Paperplanes Paperplanes Paperplanes
Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later